The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics

Expert Opinion on Investigational Drugs

Volumn 14, Issue 5, 2005, Pages 601-618

  Atack, John R ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 CHLOROPHENYL) 5,6 DIHYDRO [1]BENZOTHIEPINO[5,4 C]PYRIDAZIN 3(2H) ONE 7 OXIDE; 2 BENZOYL 6 ETHYL 7 METHOXY 5 METHYLIMIDAZO[1,2 A]PYRIMIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; 7 CHLORO 5 [(3,5 DIMETHYLPIPERAZINO)CARBONYL]IMIDAZO[1,5 A]QUINOLINE 3 CARBOXYLIC ACID TERT BUTYL ESTER; 7 CHLORO 5,6 DIHYDRO 3 (5 ISOPROPYL 1,2,4 OXADIAZOL 3 YL) 5 METHYL 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPIN 6 ONE; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ABECARNIL; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; BRETAZENIL; BUSPIRONE; DIAZEPAM; DIVAPLON; ELB 139; FLUMAZENIL; IMIDAZENIL; MIDAZOLAM; NEUROLEPTIC AGENT; NS 2664; NS 2710; OCINAPLON; PAGOCLONE; PANADIPLON; PARTIAL AGONIST; PAZINACLONE; RWJ 51204; SL 654198; UNCLASSIFIED DRUG; ZOLPIDEM; ZOPICLONE;

ANXIETY DISORDER; ATAXIA; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; CLINICAL TRIAL; DIZZINESS; DRUG ABUSE; DRUG BINDING SITE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MEMORY DISORDER; NONHUMAN; RESPIRATORY FAILURE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; WITHDRAWAL SYNDROME;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; BINDING SITES; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; RECEPTORS, GABA-A;

EID: 20344392658     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.5.601     Document Type: Review

References (125)

1. ESTES JW: The road to tranquility: the search for selective anti-anxiety agents. Synapse (1995) 21:10-20.
2. ARGYROPOULOS SV, NUTT DJ: The use of benzodiazepines in anxiety and other disorders. Eur. Neuropsychapharmacol. (1999) 9(Suppl. 6):S391-S392.
3. SHADER RI, GREENBLATT DJ: Use of benzodiazepines in anxiety disorders. N. Engl. J. Med. (1993) 328:1398-1405.
4. GORMAN JM: Treating generalized anxiety disorder. J. Clin. Psychiatry (2003) 64(Suppl. 2):24-29.
5. WOODS JH, WINGER G: Current benzodiazepine issues. Psychopharmacol. (1995) 118:107-115.
6. BUFFET-JERROTT SE, STEWART SH: Cognitive and sedative effects of benzodiazepine use. Curr. Pharm. Des. (2002) 8:45-58.
7. CUMMING RG, LE COUTER DG: Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs (2003) 17:825-837.
8. SCHWEIZER E, RICKELS K: Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Pychiatr. Scand. Suppl. 1998 (1998) 393:95-101.
9. CHOUINARD G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J. Clin. Psychiatry (2004) 65(Suppl. 5):7-12.
10. FRICCHIONE G: Clinical practice. Generalized anxiety disorder. N. Engl. J. Med. (2004) 351:675-682.
11. ASHTON H: Benzodiazepine abuse. In: Drink, Drugs and Dependence - From Science to Clinical Practice. Caan W, de Belleroche J (Eds) London, UK (2002):197-211.
12. ROBERTSON JR, TREASURE W: Benzodiazepine abuse - nature and extent of the problem. CNS Drugs (1996) 5:137-146.
13. WOODS JH: Problems and opportunities in regulation of benzodiazepines. J. Clin. Pharmacol. (1998) 38:773-782.
14. WOODS JH, WINGER G: Abuse liability of flunitrazepam. J. Clin. Psychopharmacol. (1997) 17(Suppl. 2):1S-57S.
15. GRIFFITHS RR, WOLF B: Relative abuse liability of different benzodiazepines in drug abusers. J. Clin. Psychopharmacol. (1990) 10:237-243.
16. WEINTRAUB M, SINGH S, BYRNE L, MAHARAJ K, GUTTMACHER L: Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. J. Am. Med. Assoc. (1991) 266:2392-2397.
17. UHLENHUTH EH, BALTER MB, BAN TA, YANG K: International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. J. Clin. Psychopharmacol. (1999) 19(Suppl. 2):23S-29S.
18. UHLENHUTH EH, BALTER MB, BAN TA, YANG K: Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997. Eur. Neuropsychopharmacol. (1999) 9(Suppl. 6):S393-S398.
19. COSTA E, GUIDOTTI A, MAO CC: Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum. Adv. Biochem. Psychopharmacol. (1975) 14:113-130.
20. HAEFELY W, KULCSAR A, MOHLER H, PIERI L, POLC P, SCHAFFNER R: Possible involvement of GABA in the central actions of benzodiazepines. Adv. Biochem. Psychopharmacol. (1975) 14:131-151.
21. CHOI DW, FARB DH, FISCHBACH GD: Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures. Nature (1977) 269:342-344.
22. 3H-diazepam binding. Proc. Natl. Acad. Sci. USA (1977) 74:3805-3809.
23. 3H]diazepam binding to benzodiazepine receptors in rat cerebral cortex. Life Sci. (1977) 20:2101-2110.
24. MOHLER H, OKADA T: The benzodiazepine receptor in normal and pathological human brain. Br. J. Psychiatry (1978) 133:261-278.
25. TALLMAN JF, GALLAGHER DW. The GABA-ergic system: a locus of benzodiazepine action. Ann. Rev. Neurosci. (1985) 8:21-44.
26. B sites in rat brain. Nature (1981) 290:149-152.
27. KLEPNER CA, LIPPA AS, BENSON DI, SANO MC, BEER B: Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors. Pharmacol. Biochem. Behav. (1979) 11:457-462.
28. SQUIRES RF, BENSON DI, BRAESTRUP C et al.: Some properties of brain specific benzodiazepine receptors: New evidence for multiple receptors. Pharmacol. Biochem. Behav. (1979) 10:825-830.
29. 3H]Propyl β-carboline-3-carboxylate as a selective ligand for the BZ1 benzodiazepine receptor subclass. J. Neurochem. (1981) 37:333-341.
30. SIEGHART W, SCHUSTER A: Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Biochem. Pharmacol. (1984) 33:4033-4038.
31. SIGEL E, BARNARD EA: A γ-aminobutyric acid/benzodiazepine receptor complex from bovine cerebral cortex. Improved purification with preservation of regulatory sites and their interactions. J. Biol. Chem. (1984) 259:7219-7223.
32. A receptor shows a ligand-gated receptor super-family. Nature (1987) 328:221-227.
33. A receptor heterogeneity. Nature (1988) 335:76-79.
34. A-benzodiazepine receptors produced in transfected cells. Science (1989) 245:1389-1392.
35. A receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev. (1998) 50:291-313.
36. A receptor structure relieved by AChBP. Trends Biochem. Sci. (2002) 27:280-287.
37. A receptor genes in the human genome. J. Biol. Chem. (2004) 279:41422-41435.
38. BORMAN J: The 'ABC' of GABA receptors. Trends Pharmacol. Sci. (2000) 21:16-19.
39. A-receptor subtypes really occur in the brain? Trends Neurosci. (1996) 19:139-143.
40. A receptor subtypes. Curr. Top. Med. Chem. (2002) 2:795-816.
41. MINIER F, SIGEL E: Techniques: use of concatenated subunits for the study of ligand-gated ion channels. Trends Pharmacol. Sci. (2004) 25:499-503.
42. A receptor subtypes. Pharmacol. Rev. (1995) 47:181-234.
43. 5-subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem. (1990) 54:1802-1804.
44. 4 subunit. FEBS Lett. (1991) 289:227-230.
45. A receptors is essential for benzodiazepine agonist binding. J. Biol. Chem. (1992) 267:1426-1429.
46. A receptors rendered diazepam-insensitive by point-mutated α-subunits. FEBS Lett. (1998) 431:400-404.
47. A receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu. Rev. Pharmacol. Toxicol. (2004) 44:475-498.
48. MOROZ G: High-potency benzodiazepines: recent clinical results. J. Clin. Psychiatry (2004) 65(Suppl. 5):13-18.
49. HUNKELER W, MOHLER H, PIERI L et al.: Selective antagonists of benzodiazepines. Nature (1981) 290:514-516.
50. A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J. Neurosci. (1992) 12:1040-1062.
51. A receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. (1995) 359:154-194.
52. A receptor subunits in the rat hippocampus: I. Immuncytochemical distribution of 13 subunits. Neuroscience (1997) 80:987-1000.
53. A receptors: Immunocytochemical distribution of 13 subunits in the adult brain. Neurosci. (2000) 101:815-850.
54. A receptor subtypes as potential drug targets by using genetically modified mice. Curr. Drug Targets - CNS Neurol. Dis. (2003) 2:53-59.
55. A receptor subunit mutant mice: new perspectives on alcohol actions. Biochem. Pharmacol. (2004) 68:1581-1602.
56. A receptor subtype to the pharmacological actions of benzodiazepine site inverse agonists. Neuropharmacology (2002) 43:679-684.
57. KOPP C, RUDOLPH U, TOBLER I: Sleep EEG changes after zolpidem in mice. Neuroreport (2004) 15:2299-2302.
58. RUDOLPH U, CRESTANI F, BENKE D et al.: Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes. Nature (1999) 401:796-800.
59. 1 subtype. Nat. Neurosci. (2000) 3:587-592.
60. LOW K, CRESTANI F, KEIST R et al.: Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 290:131-134.
61. CRESTANI F, LOW K, KEIST R, MANDELLI M-J, MOHLER H, RUDOLPH U: Molecular targets for the myorelaxant action of diazepam. Mol. Pharmacol. (2001) 59:442-445.
62. A receptor subtype. Proc. Natl. Acad. Sci. USA (2001) 98:6464-6469.
63. A receptor subtype. Eur. J. Neurosci. (2003) 17:2226-2230.
64. A receptors. Proc. Natl. Acad. Sci. USA (2002) 99:8980-8985.
65. A receptor. J. Neurosci. (2002) 22:5572-5580.
66. 5 receptors with cognition enhancing properties. J. Med. Chem. (2004) 47:5829-5832.
67. 5 receptor inverse agonists as cognition enhancers. J. Med. Chem. (2004) 47:2176-2179.
68. 5 benzodiazepine binding site. J. Med. Chem. (2004) 47:3642-3657.
69. A receptors. Br. J. Pharmacol. (2005) 144:357-366.
70. LE DOUX JE: Emotion circuits in the brain. Ann. Rev. Neurosci. (2000) 23:155-184.
71. WALKER DL, TOUFEXIS DJ, DAVIS M: Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur. J. Pharmacol. (2003) 463:199-216.
72. HAEFELY W, MARTIN JR, SCHOCH P: Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci. (1990) 11:452-456.
73. COSTA E, GUIDOTTI A: Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol. Sci. (1996) 17:192-200.
74. A receptor benzodiazepine binding site. Curr. Drug Targets - CNS Neurol. Disorders (2003) 2:213-232.
75. A receptors. J. Pharmacol. Expt. Therap. (1993) 266:1018-1028.
76. A receptor diversity emerges a unified vision of GABAergic inhibition. Annu. Rev. Pharmacol. Toxicol. (1998) 38:321-350.
77. A receptors. Soc. Neurosci. Abstr. (2001) 491:8.
78. MIRZA NR, NIELSEN EO, JOHANSEN TH et al.: NS2664: An atypical benzodiazepine site ligand. 2003 Abstract Viewer/Itinerary Planner. Society for Neuroscience Washington DC. (2003) 959:8.
79. 36Cl ion flux. Mol. Pharmacol. (2001) 59:1108-1118.
80. FLECK MW: Molecular actions of (S)-desmethylzopiclone (SEP-174559), an anxiolytic metabolite of zopiclone. J. Pharmacol. Exp. Therap. (2002) 302:612-618.
81. CARLSON JN, HASKEW R, WACKER J, MAISONNEUVE IM, GLICK SD, JERUSSI TP: Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur. J. Pharmacol. (2001) 415:181-189.
82. McMAHON LR, JERUSSI TP, FRANCE CP: Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys. Psychopharmacol. (2003) 165:222-228.
83. DUBINSKY B, VAIDYA AH, ROSENTHAL DI et al.: 5-Ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo [4,5]imidazo [1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J. Pharmacol. Expt. Therap. (2002) 303:777-790.
84. GARDNER CR, DEACON R, GUY AP, MANN G, BUDHRAM P, MILLER P: RU 32698, a new benzodiazepine receptor ligand with anxiolytic but little sedative/myorelaxant properties. Br. J. Pharmacol. (1987) 92:537P.
85. ADIS: Y 23684. Drugs R & D (1999) 2:68-69.
86. ZONG WZ, WILLIAMS MG, BRANSTETTER DG: Toxicokinetics in drug development: an overview of toxicokinetic application in the development of PNU-101017, an anxiolytic drug candidate. Curr. Drug Metab. (2000) 1:243-254.
87. ULRICH RG, BACON JA, BRANSTETTER DG et al.: Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic. Toxicology (1995) 98:187-198.
88. ULRICH RG, BACON JA, BRASS EP, CRAMER CT, PETRELA DK, SUN EL: Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem. Biol. Interact. (2001) 134:251-270.
89. VAN STEVENINCK AL, GIESCHKE R, SCHOEMAKER RC et al.: Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br. J. Clin. Pharmacol. (1996) 41:565-573.
90. DELINI-STULA A, BERDAHTORDJMAN D: Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia-a study group report. J. Pychiatr. Res. (1996) 30:239-250.
91. EVANS SM, FOLTIN RW, LEVIN FR, FISCHMAN MW: Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav. Pharmacol. (1995) 6:176-186.
92. LINDEN M, HADLER D, HOFMAN S: Randomised, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety. Hum. Psychopharmacol. Clin. Exper. (1997) 12:445-452.
93. MUMFORD GK, RUSH CR, GRIFFITHS RR: Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol. Expt. Therap. (1995) 272:570-80.
94. LYDIARD RB, BALLENGER JC, RICKELS K: A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J. Clin. Psychiatry (1997) 58(Suppl. 11): 11-18.
95. POLLACK MH, WORTHINGTON JJ, MANFRO GG, OTTO MW, ZUCKER BG: Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J. Clin. Psychiatry (1997) 58(Suppl. 11): 19-23.
96. AUFDEMBRINKE B: Abecarnil, a new β-carboline, in the treatment of anxiety disorders. Br. J. Psychiatry (1998) 173(Suppl. 34):55-63.
97. RICKELS K, DeMARTINIS N, AUFDEMBRINKE B: A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J. Clin. Psychopharmacol. (2000) 20:12-18.
98. 5 subunit. Neuropharmacology (1996) 35:1331-1335.
99. 5-subunits. J. Pharmacol. Exp. Therap. (1997) 283:488-493.
100. A receptors. Expert Opin. Ther. Patents (1999) 9:1347-1358.
101. A receptor function as CNS therapeutics. Expert Opin. Ther. Patents (2002) 2:1491-1501.
102. A receptor-ion channels. J. Med. Chem. (2002) 45:1887-1900.
103. 5 receptor inverse agonists. J. Med. Chem. (2002) 45:1176-1179.
104. 5 receptor inverse agonist which enhances cognition. J. Med. Chem. (2003) 46:2227-2240.
105. A receptors. Bioorg. Med. Chem. Lett. (2004) 14:2871-2875.
106. JOHNSTONE TB, HOGENKEMP DJ, COYNE L et al.: Modifying quinolone antibiotics yields new anxiolytics. Nature Med. (2004) 10:31-32.
107. A receptor positive modulators. FENS Abstr. (2004) 2:A164:13.
108. A receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Acad. Sci. USA (2005) 102:915-920.
109. ROSTOCK A, TOBER C, DOST R et al.: AWD-131-138. Drugs Future (1998) 23:253-255.
110. MEALY NE, BAYES M: Treatment of psychiatric disorders. Drugs Fut. (2004) 29:923-977.
111. A) receptors. J. Pharmacol. Expt. Therap. (2001) 298:753-768.
112. A receptor agonist with subtype-selective efficacy, as a potential treatment for Generalized Anxiety Disorder and muscle spasms. CNS Drug Rev. (2003) 9:3-20.
113. A /benzodiazepine receptor complex and behavioral effects in the rodent. J. Pharmacol. Exp. Therap. (1993) 266:1213-1226.
114. BATESON A: Pagoclone Indevus. Curr. Opin. Investig. Drugs (2003) 4:91-95.
115. ATACK JR, PIKE A, MARSHALL G et al.: The in vivo properties of pagoclone in rat are mediated by the hydroxylated metabolite. 2004 Abstract viewer/Itinerary Planner, Society for Neuroscience, Washington D.C. (2004) 844:9.
116. 11C] flumazenil positron emission tomography study? Int. J. Neuropsychopharmacol. (2000) 3(Suppl. 1):S288.
117. SANDFORD JJ, FORSHALL S, BELL C et al. Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J. Psychopharmacol. (2001) 15:205-208.
118. SORBERA LA, LEESON PA, SILVESTRE J, CASTANER J: Pagoclone. Drugs Fut. (2001) 26:651-657.
119. KAVOUSSI RJ, PANDE AC, LYDIARD RB, PAPP L, PIGOTT TA, RICKELS K: Efficacy and safety of pagoclone, a novel GABA modulator in the treatment of panic disorder with or without agoraphobia. Int. J. Neuropsychopharmacol. (2000) 3(Suppl. 1):S280.
120. VANOVER KE, ZHANG L, BARRETT JE: Discriminative stimulus and anxiolytic-like effects of the novel compound CL 273,547. Exp. Clin. Psychopharmacol. (1994) 2:223-233.
121. A receptor by ocinaplon, an anxioselective pyrazolopyrimidine. Abstract Viewer/ Itinerary Planner. Society for Neuroscience, 2003, Washington DC (2003) 48.3.
122. A receptor modulator, in Generalized Anxiety Disorder. Abstract Viewer/Itinerary Planner. Society for Neuroscience, 2002, Washington DC (2002) 396:15.
123. CHILMAN-BLAIR K, CASTANER J, SILVESTRE JS: Ocinaplon. Drugs Future (2003) 28:115-120.
124. CZOBOR P, STARK J, BEER G et al.: A double-blind, placebo controlled study of DOV 273,547 (ocinaplon) in the treatment of generalized anxiety disorder (GAD). Abstract Viewer/Itinerary Planner. Society for Neuroscience, 2003, Washington DC (2003) 959.12.
125. LEWIS DA, VOLK DW, HASHIMOTO T: Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl.) (2004) 174:143-150.